Open Access. Powered by Scholars. Published by Universities.®
Hematology/Oncology and Stem Cell Therapy
Carfilzomib; Proteasome inhibitors; Thrombotic microangiopathy
Articles 1 - 1 of 1
Full-Text Articles in Cancer Biology
Carfilzomib-Induced Thrombotic Microangiopathy: A Case Based Review, Nishant Jindal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Ritambhra Nada, Jasmine Sethi, Jasmina Ahluwalia, Pankaj Malhotra
Carfilzomib-Induced Thrombotic Microangiopathy: A Case Based Review, Nishant Jindal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Ritambhra Nada, Jasmine Sethi, Jasmina Ahluwalia, Pankaj Malhotra
Hematology/Oncology and Stem Cell Therapy
Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.